Jennifer Doudna

Jennifer Doudna is an American biochemist known for her pioneering work in the field of genome editing. She was born on February 19, 1964, in Washington, D.C. Doudna earned her Bachelor of Arts degree in Biochemistry from Pomona College and later obtained her Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University. Doudna is currently a professor at the University of California, Berkeley, where she holds appointments in the Department of Molecular and Cell Biology and the Department of Chemistry. She is also a co-founder of several biotechnology companies. Her most notable work includes the development of the CRISPR-Cas9 gene-editing technology, which allows for precise modifications to DNA in living organisms. This groundbreaking technology has had a profound impact on genetics, molecular biology, and medicine, enabling advancements in areas such as gene therapy, agriculture, and disease research. In recognition of her contributions, Doudna was awarded the Nobel Prize in Chemistry in 2020, alongside Emmanuelle Charpentier, for their work on CRISPR-Cas9.

Jennifer A. Doudna is an American biochemist renowned for her pioneering work in CRISPR-Cas9 gene editing. Born on February 19, 1964, in Washington, D.C., she earned her bachelor’s degree in biochemistry from Pomona College (1985) and her Ph.D. in biological chemistry and molecular pharmacology from Harvard Medical School (1989). Currently, Doudna holds the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences and is a professor in the Departments of Chemistry and Molecular and Cell Biology at the University of California, Berkeley. She is also an Investigator of the Howard Hughes Medical Institute (HHMI) and the founder and president of the Innovative Genomics Institute (IGI), a collaboration between UC Berkeley and UCSF established in 2014 to advance CRISPR technologies for human health, climate, and agriculture. Her most notable work includes co-developing CRISPR-Cas9 as a precise, efficient, and affordable genome-engineering tool with French microbiologist Emmanuelle Charpentier. In 2012, they demonstrated that CRISPR-Cas9 could be used to make targeted changes to DNA in animal cells, revolutionizing genetic research. For this breakthrough, Doudna and Charpentier were awarded the 2020 Nobel Prize in Chemistry. Doudna has also founded multiple biotech companies (e.g., Caribou Biosciences, Mammoth Biosciences) to commercialize CRISPR technologies and holds over 100 U.S. patents. She is a leading advocate for the ethical and responsible use of gene editing.

# Jennifer Doudna Jennifer Doudna is a biochemist and molecular biologist known for her foundational work on CRISPR gene-editing technology. **Background:** - Earned her Ph.D. in biochemistry from Harvard University - Trained as a structural biologist **Current Role:** - Professor of Chemistry and Molecular and Cell Biology at UC Berkeley - Co-director of the Innovative Genomics Institute at Berkeley **Notable Work:** - Co-developed CRISPR-Cas9 gene editing with Emmanuelle Charpentier (published 2012) - Their work demonstrated how to use the bacterial immune system as a precise tool for editing DNA - Awarded the Nobel Prize in Chemistry in 2020 (shared with Charpentier) for this discovery **Other Contributions:** - Active in discussing ethical implications of gene editing, including concerns about germline editing - Published a memoir, *A Crack in Creation* (2017) CRISPR-Cas9 has become one of the most significant biotechnology tools, with applications in research, medicine, and agriculture.

Jennifer Doudna is an American biochemist known for her pioneering work in genome editing. **Background:** * Born in Washington, D.C., in 1964. * Earned her B.A. in Chemistry from Pomona College in 1985. * Received her Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School in 1989. **Current Role:** * Professor of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley. * Investigator at the Howard Hughes Medical Institute. * Executive Director of the Innovative Genomics Institute (IGI), a joint UC Berkeley-UCSF initiative. **Notable Work:** * **Co-discovery of CRISPR-Cas9 as a gene-editing tool:** In 2012, Doudna, along with Emmanuelle Charpentier, published a groundbreaking paper demonstrating that the bacterial CRISPR-Cas9 system could be reprogrammed to edit DNA with high precision. This discovery revolutionized genetic engineering. * **Nobel Prize in Chemistry:** For this work, Doudna and Charpentier were awarded the Nobel Prize in Chemistry in 2020, becoming the first two women to share the prize without a male collaborator. * **Advocacy for ethical considerations:** Doudna has been a prominent voice in discussions about the ethical implications of gene editing, advocating for responsible research and clear guidelines for its use. * **Research on RNA structure and function:** Prior to her work on CRISPR, Doudna conducted significant research on the structure and function of RNA, including catalytic RNA (ribozymes).

**Jennifer Doudna** is a Nobel Prize-winning biochemist who is a central figure in the development of CRISPR-Cas9 genome editing technology. **Background:** * **Education:** She earned a B.A. in Biochemistry from Pomona College (1985) and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School (1989). * **Early Career:** She conducted postdoctoral research at the University of Colorado Boulder and later held faculty positions at Yale University and the University of California, Berkeley. **Current Role:** * She is a **Professor of Chemistry and Molecular & Cell Biology** at the University of California, Berkeley. * She is the **Founder and Chair of the Innovative Genomics Institute (IGI)**, a joint UC Berkeley and UCSF initiative. * She is a **Senior Investigator at the Gladstone Institutes**. * She is a co-founder of several biotech companies, most notably **Intellia Therapeutics**, a clinical-stage company developing CRISPR-based therapies. **Notable Work:** * **CRISPR-Cas9 Genome Editing:** Her most famous achievement, in collaboration with Emmanuelle Charpentier, was the **2012 biochemical characterization of the CRISPR-Cas9 system as a programmable tool for precise DNA editing**. This work, published in *Science*, revolutionized genetic engineering. * **Nobel Prize:** For this discovery, she and Charpentier were awarded the **2020 Nobel Prize in Chemistry**. * **Ongoing Research:** Her lab continues to pioneer new CRISPR systems (like Cas12 and Cas13), develop therapeutic applications (e.g., for sickle cell disease and genetic blindness), and advance fundamental understanding of RNA biology. * **Leadership in Ethics:** She has been a leading voice in calling for **international discussions on the ethical implications of human genome editing**, notably co-organizing the 2015 International Summit on Human Gene Editing. In summary, Jennifer Doudna is a pioneering biochemist whose work on CRISPR-Cas9 created a transformative technology for genetic research and medicine, earning her the highest scientific accolades.

Jennifer Doudna (born 1964) is an American biochemist and professor of chemistry and molecular/cell biology at UC Berkeley, where she holds the Li Ka Shing Chancellor's Chair. She is best known for co-discovering the CRISPR-Cas9 genome-editing mechanism with Emmanuelle Charpentier; the pair shared the 2020 Nobel Prize in Chemistry for this work. Doudna also co-founded several biotech companies applying the technology (e.g., Caribou Biosciences, Intellia Therapeutics) and is an HHMI investigator.

Jennifer Doudna is a renowned American biochemist who has made significant contributions to the field of genome editing. Here is a concise factual summary of her background, current role, and notable work: **Background:** Jennifer Doudna was born in 1964 in Washington, D.C. She earned her Bachelor's degree in Biochemistry from Pomona College in 1985 and her Ph.D. in Biochemistry from Harvard University in 1989. **Current Role:** Doudna is currently a Professor of Biochemistry, Biophysics, and Structural Biology at the University of California, Berkeley, and a Senior Investigator at the Gladstone Institutes. **Notable Work:** Doudna is best known for her pioneering work on the CRISPR-Cas9 gene editing tool, which has revolutionized the field of genetics and biotechnology. In 2012, she and her colleague Emmanuelle Charpentier discovered that the CRISPR-Cas9 system could be used to edit genes in a precise and efficient manner. This breakthrough has led to numerous applications in basic research, biotechnology, and medicine, including the development of new therapies for genetic diseases. Doudna has received numerous awards for her work, including the Breakthrough Prize in Life Sciences, the Gruber Prize in Genetics, and the Wolf Prize in Medicine. She is also a member of the National Academy of Sciences and the National Academy of Medicine.